We searched MEDLINE and the Cochrane Library with the terms “myasthenia gravis”, “myasthenic syndromes”, and “myasthenia” from January 1995, to April, 2015. Guideline and review papers were assessed in detail, and controlled studies sought for in particular. Papers were selected by title and abstract. Only papers in English were included. Randomised trials on established and emerging therapies for myasthenia gravis are often scarce, so our recommendations are based on the best available
ReviewMyasthenia gravis: subgroup classification and therapeutic strategies
Introduction
Dysfunction at the neuromuscular junction underlies several disorders that are characterised by skeletal muscle weakness usually involving some but not all muscle groups. Genetic forms of these disorders are termed congenital myasthenic syndromes. Some toxins, like botulinum toxin and curare, can cause neuromuscular dysfunction; acquired antibody-mediated forms include autoimmune and neonatal myasthenia gravis, Lambert–Eaton myasthenic syndrome, and neuromyotonia.
Myasthenia gravis forms the largest disease group of neuromuscular junction disorders and is caused by pathogenic autoantibodies to components of the postsynaptic muscle endplate (figure 1).1, 2, 3, 4 Fluctuations in severity of muscle weakness are typical. Some, but not all, muscles are affected and not necessarily symmetrically. Increased weakness with continued muscle activity represents a diagnostic clue for myasthenia gravis, but these clinical features can vary. Patients with myasthenia gravis should be classified into subgroups, with implications for diagnosis, optimum therapy, and prognosis. In myasthenia gravis guidelines and consensus reports, subgrouping is recommended,1, 2, 3, 4, 5 but exact definitions vary and new subgroups are emerging as a result of increased knowledge. As this subgrouping takes into account myasthenia gravis autoantibodies, epidemiology, clinical presentation, and comorbidities, the subgroups are discussed after these sections in this Review. For a few patients, subgrouping is not possible owing to insufficient precise information, including suboptimum autoantibody testing and pathological changes of the thymus below the detection threshold of imaging.
Autoantibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MUSK), and lipoprotein-related protein 4 (LRP4) are well established as sensitive and specific diagnostic markers and pathogenic factors, and these autoantibodies are instrumental for subgrouping patients with myasthenia gravis. A prerequisite for optimum diagnosis and treatment, therefore, is access to autoantibody testing.1, 2, 3, 4, 5
With modern immunosuppressive, symptomatic, and supportive treatments, the prognosis for patients with myasthenia gravis is good. Most patients with mild-to-moderate symptoms will obtain full remission or substantial improvement. Full remission is rare in severe cases, some variation over time is common, and steady progression is unusual. Daily life functions of individuals with myasthenia gravis are not, or only modestly, affected and life expectancy is not reduced.6 Long-term drug treatment is necessary for nearly all patients with myasthenia gravis.2, 7 In 10–15% of these patients, full control of the disease is not possible or is only at the cost of severe side-effects of immunosuppressive therapy.8
Treatment protocols at leading centres are not based purely on results from well controlled studies or guidelines based on such studies, because well controlled studies are sparse for this disease, and do not take into account the variation in therapeutic response among the diagnostic subgroups. Myasthenia gravis is a rare disease, and most patients do well on existing treatments, both aspects that are a challenge for new trials. We will combine information from controlled studies, consensus reports, and expert views with insights from theoretical and experimental studies relevant for myasthenia gravis subgroups, with the aim of assessing the evidence base for the use of treatments, including interventions directed at the pathophysiological process.
Section snippets
Autoantibodies in myasthenia gravis
AChR antibodies are highly specific for myasthenia gravis, and their presence combined with muscle weakness confirms the disease. Further diagnostic investigation is necessary only to define the subgroup and disease severity. The value of repeated AChR antibody testing in patients with this disorder is debated, but changes in antibody concentration might predict disease severity in patients given immunosuppressive drugs and therefore can support therapeutic decisions. No correlation has been
Epidemiology
Autoimmune myasthenia gravis has a reported worldwide prevalence of 40–180 per million people, and an annual incidence of 4–12 per million people.20, 21, 22, 23 Recently collected figures of prevalence and incidence tend to be higher than older ones, especially for late-onset myasthenia gravis, partly explained by increased case finding and more widespread autoantibody testing. Population demographics with an increased number of elderly people and reduced myasthenia gravis mortality affect
Clinical presentation
Muscle weakness is a major symptom and sign in myasthenia gravis. The combination of weakness localisation, variation in weakness over time, and exercise-induced weakness usually gives strong clues to the diagnosis of the disease for all subgroups. In older individuals with eye muscle weakness and bulbar symptoms, cerebrovascular disease of the brainstem is sometimes suspected. In younger individuals, unspecific fatigue disorders can be part of the differential diagnoses.1, 3, 7
Weakness in
Comorbidities
Patients with early-onset and ocular subgroups of myasthenia gravis have increased frequency of organ-specific and general autoimmune disorders, especially thyroiditis.29 Patients with thymoma-associated myasthenia gravis are at an increased risk of developing haematological autoimmune disorders. Thymectomies have not been shown to increase the risk of infections, autoimmune disease, or cancer. Myasthenia gravis muscle weakness might increase the risk of respiratory infections and osteoporosis,
Early-onset myasthenia gravis with AChR antibodies
Patients with early-onset myasthenia gravis have, by definition, onset of their first symptom before age 50 years (table 1).1, 7, 39 Serum AChR antibodies are detected by standard diagnostic testing. Patients with a thymoma detected on imaging or during surgery are excluded from this myasthenia gravis subgroup. Thymic follicular hyperplasia occurs often but is not a prerequisite, and this group responds to thymectomy. Female cases outnumber male cases by three to one.20, 22 Early-onset
Thymus pathological changes
Thymoma, but no other thymic tumours, is associated with myasthenia gravis. Thymic hyperplasia is reported in most patients with early-onset myasthenia gravis and in some patients with late-onset, ocular, and antibody-negative disease. CT scanning or MRI of the mediastinum should be undertaken in all patients with myasthenia gravis to assess for a thymoma.1, 2, 3, 4, 7 Both sensitivity and specificity are challenges for imaging.
Experimental and clinical evidence strongly suggests that
Neurophysiological testing
Neurophysiological tests are unnecessary in patients with typical myasthenia gravis symptoms because diagnosis can be confirmed by specific antibody tests; these tests are also not helpful for myasthenia gravis subgroup classification. However, they are important for correct diagnosis in patients with myasthenia gravis without detectable autoantibodies.
Repetitive nerve stimulation and single-fibre electromyography for an increased jitter are useful tests for patients with myasthenia gravis.
Symptomatic drug treatment
Drugs that increase the amount of acetylcholine at neuromuscular endplates after motor nerve stimulation improve muscle weakness in all myasthenia gravis subgroups; pyridostigmine is the preferred drug for symptomatic treatment.7 Other acetylcholinesterase inhibitors, such as neostigmine and ambenonium chloride, have different durations of action and can differ regarding side-effects. The improvement reported in patients with these drugs is so specific that it is used as a diagnostic clue in
Treatment of myasthenia gravis crisis
Crisis is defined as a need for intubation for respiratory support caused by muscle weakness related to the disease. Treatment includes intensive care with respiratory support, treatment of infections, and monitoring of vital functions and mobilisation (figure 5). Intravenous immunoglobulin and plasma exchange are specific immunosuppressive treatments with a rapid effect occurring after 2–5 days, and either one should be given to patients with severe myasthenia gravis exacerbations and always
Treatment of myasthenia gravis in pregnancy
Pregnancy does not affect myasthenia gravis in any consistent way, with no increased risk of severe deterioration or myasthenia gravis crisis.85, 104, 105 During the first weeks and few months post partum, the risk of symptom worsening is moderately increased, mainly because of stress and new demands.
Pyridostigmine and corticosteroids are regarded as safe treatments for pregnant women.85 These drugs do not increase the risk of fetal malformations or delayed fetal development. Plasma exchange
Treatment of neonatal myasthenia gravis
Neonatal myasthenia gravis occurs in 10–15% of babies of mothers with the disease. The cause of this transient muscular weakness in these babies is transfer of the mother's AChR or MUSK antibodies of the IgG class across the placenta. This weakness usually lasts for only days or a few weeks and is typically mild but can interfere with feeding and respiration. Mothers with myasthenia gravis should always give birth at hospitals experienced in respiratory support treatment for newborn babies. The
Conclusions and future directions
Most patients with myasthenia gravis do well and have well controlled disease. However, most need long-term and often life-long drug treatment with acetylcholinesterase inhibitors and usually low-dose immunosuppression. Pathogenic autoantibodies are well characterised and myasthenia gravis subgroups are defined accordingly. However, treatment is far from antibody specific and is not even specific to the disease subgroup. Many new and more traditional drugs that have not been tested properly in
Search strategy and selection criteria
References (112)
- et al.
Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4
Autoimmun Rev
(2013) - et al.
Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens
Autoimmun Rev
(2013) - et al.
Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China
J Neurol Sci
(2011) - et al.
Cortactin autoantibodies in myasthenia gravis
Autoimmun Rev
(2014) - et al.
Limb-girdle myasthenia; clinical, electrophysiological and morphological features in familial and autoimmune cases
Neuromuscul Disord
(2002) - et al.
Serial measurements of cardiac troponin I in patients with myasthenia gravis-related cardiomyopathy
Int J Cardiol
(2013) - et al.
Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis
Hum Immunol
(2013) - et al.
The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes
Autoimmun Rev
(2013) - et al.
Muscle specific kinase autoimmune myasthenia gravis in children: a case series
Neuromuscul Disord
(2013) - et al.
Association of HLA-DR131*14,-DR131*16 and –DQB1*05 with MuSK-myasthenia gravis in patients from Turkey
Hum Immunol
(2013)
Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules
J Neuroimmunol
Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis
J Neurol Sci
A double-blinded, randomized, placebo-controlled trial to evaluate efficacy, safety and tolerability of single doses of tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis
Neurotherapeutics
Myasthenia gravis: recommendations for clinical research standards
Ann Thorac Surg
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
Lancet Neurol
Myasthenia and neuromuscular junction
Curr Opin Neurol
Myasthenia and the neuromuscular junction
Curr Opin Neurol
Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001
J Neurol Neurosurg Psychiatry
Guidelines for treatment of autoimmune neuromuscular transmission disorders
Eur J Neurol
Clinical characteristics of refractory myasthenia gravis patients
Yale J Biol Med
Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis
Arch Neurol
Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to dissembly of the ACh receptor scaffold and myasthenia gravis in mice
J Physiol
Anti-MuSK autoantibodies block binding of collagen Q to MuSK
Neurology
Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis
Ann NY Acad Sci
Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis
J Clin Invest
Anti-agrin autoantibodies in myasthenia gravis
Neurology
Autoantibodies to agrin in myasthenia gravis
PLoS One
Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro
Muscle Nerve
Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features
Eur J Neurol
Seropositive myasthenia gravis; a nationwide epidemiologic study
Neurology
Myasthenia gravis requiring pyridostigmine treatment in a national population cohort
Eur J Neurol
A systematic review of population based epidemiological studies in myasthenia gravis
BMC Neurol
Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada
Neurology
Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996–2009
Eur J Neurol
Clinical characteristics of pediatric myasthenia: a surveillance study
Pediatrics
Epidemiology of myasthenia gravis witht anti-muscle specific kinaase antibodies in the Netherlands
J Neurol Neurosurg Psychiatry
Anti-MuSK antibody myasthenia gravis; clinical findings and response to treatment in two large cohorts
Muscle Nerve
Myasthenia gravis and risks for comorbidity
Eur J Neurol
Immune-mediated rippling muscle disease; another inflammatory myopathy in myasthenia gravis
Arch Neurol
Amyotrophic lateral sclerosis with positive anti-acetylcholine receptor antibodies; case report and review of the literature
J Clin Neuromuscul Dis
Thymoma and the increased risk of developing extrathymic malignancies: a multicentre study
Eur J Cardiothor Surg
Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark
Eur J Neurol
Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine
Eur J Neurol
Left ventricular long-axis function in myasthenia gravis
J Neurol
Autoimmune targets of heart and skeletal muscles in myasthenia gravis
Arch Neurol
Overlooked non-motor symptoms in myasthenia gravis
J Neurol Neurosurg Psychiatry
Late-onset myasthenia gravis; a review when incidence in older adults keeps increasing
Muscle Nerve
Risk for myasthenia gravis maps to a (151) pro-ala change in TNIP1 and human leukocyte antigen-B*08
Ann Neurol
A genome-wide association study of myasthenia gravis
JAMA Neurol
Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population
PLoS One
Cited by (744)
Comparison of three methods for the detection of antibodies against muscle-specific kinase
2024, Journal of Immunological MethodsEpidemiology of myasthenia gravis in France: A retrospective claims database study (STAMINA)
2024, Revue Neurologique